Transitioning from solvent-intensive peptide production to modern techniques such as enzyme-based peptide synthesis and scalable oral small molecules, such as orforglipron, presents a vast opportunity to lower costs and boost profit margins
Additionally, the references of eligible studies and relevant reviews were examined to identify further potentially relevant publications
Semaglutide GLP-1, a GLP-1 receptor agonist , mimics incretin hormones, enhancing insulin secretion, slowing gastric emptying, and reducing appetite, achieving up to 15% weight loss, with an average reduction of 12.4%
Conversely, aggressive caloric restriction without planning increases vulnerability not because GLP-1 impairs absorption, but because reduced intake changes exposure
In adults, the focus is predominantly on reversing weight regain and improving cardiometabolic parameters